Table 1

COMPARE analysis of NSC 314622 using GI50 data from the National Cancer Institute In Vitro Anticancer Drug Screen

RankNSCLHICONCMax XCORRNMechanism/class
3–350.842–0.77833 camptothecins
369706−4.001370.77760alkylating agent
37D−4.0030.776601 camptothecin
38D−4.0020.77559analog NSC 314622
39132313−3.0040.77560alkylating agent
40–520.774–0.76512 camptothecins
53D−4.0020.76460alkylating agent
54–610.763–0.7608 camptothecins
62167781−4.0040.76060alkylating agent
63–710.759–0.7519 camptothecins
72638436−4.0010.75140top1 and/or top2
73–740.751–0.7502 camptothecins
753088−3.121270.74960alkylating agent
766396−3.001300.74860alkylating agent
77–790.7473 camptothecins
80620480−4.0030.74758alkylating agent
81D−4.0020.74460bleomycin analog
82–910.744–0.74010 camptothecins
9248034−4.0020.73959alkylating agent
93D−6.0020.73958alkylating agent
94D−4.1220.739591 camptothecin
95275656−4.0030.73857alkylating agent
96–1000.737–0.7345 camptothecins
  • NSC, number key to the NCI database (D indicates discrete compound); LHICONC, decimal logarithm of the highest drug concentration tested (molar concentration); Max X, measure of the number of tests that were averaged for this compound; CORR, Pearson coefficient for the seed and the data base compound; and N, number of cell lines common to both the seed and the database compound, which therefore are used in the calculation of the CORR.